AQST - Aquestive stock falls amid Libervant approval Anaphylm update
2024-04-29 13:56:26 ET
More on Aquestive Therapeutics
- Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
- Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript
- Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Aquestive wins FDA approval for anti-seizure therapy Libervant
- Aquestive Therapeutics a new overweight at Piper on oral film products